Phillyrin: A review of its pharmacokinetics and multi-target anti-inflammatory mechanisms for therapeutic potential
- 6 December 2025
- journal article
- review article
- Published by Elsevier in Phytomedicine
- Vol. 150, 157674
Abstract
No abstract availableKeywords
Funding Information
- Anhui University of Chinese Medicine (OP2500000161)
- National Natural Science Foundation of China (82204710)
- Anhui province Department of Education (YQZD2024019)
This publication has 72 references indexed in Scilit:
- Phillyrin inhibits oxidative stress and neutrophil extracellular trap formation through the KEAP1/NRF2 pathway in gouty arthritisImmunologic Research, 2024
- Repurposing Antiviral Drugs as Potential Anti‐EGFR Agents in NSCLC: A Structure‐Based Screening and Molecular Dynamics AnalysisChemistry & Biodiversity, 2024
- Phillyrin: an adipose triglyceride lipase inhibitor supported by molecular docking, dynamics simulation, and pharmacological validationJournal of Molecular Modeling, 2024
- Management of de Quervain TenosynovitisJAMA Network Open, 2023
- Determination of six core components from Mahuang Xuanfei Zhike syrup in rat plasma and tissues by UPLC–MS/MS: Application to a pharmacokinetics and tissue distribution studyBiomedical Chromatography, 2022
- Phillyrin Relieves Lipopolysaccharide-Induced AKI by Protecting Against Glycocalyx Damage and Inhibiting Inflammatory ResponsesInflammation, 2019
- Protective effects of phillyrin against influenza A virus in vivoArchives of Pharmacal Research, 2016
- Metabolic profile of phillyrin in rats obtained by UPLC‐Q‐TOF‐MSBiomedical Chromatography, 2015
- Forsythin inhibits lipopolysaccharide-induced inflammation by suppressing JAK-STAT and p38 MAPK signalings and ROS productionInflammation Research, 2014
- Investigation on the absorption of phillyrin and forsythiaside in rat digestive tractEuropean Journal of Drug Metabolism and Pharmacokinetics, 2011